Showing results (81-90 of 366) with videos related to
Sort By:
Pageof 37
Lung Cancer (Amsterdam, Netherlands)|March 2, 2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation studyMartin Reck, Norbert Frickhofen, Susana Cedres, et al.Future Oncology (London, England)|May 30, 2023
TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLCBenjamin P Levy, Enriqueta Felip, Martin Reck, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 6, 2021
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitorsClara García-Carro, Mónica Bolufer, Roxana Bury, et al.Lung Cancer (Amsterdam, Netherlands)|May 29, 2021
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancerSanjay Popat, Odd Terje Brustugun, Jacques Cadranel, et al.Expert Opinion on Biological Therapy|September 22, 2016
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncologyCesare Gridelli, Paolo A Ascierto, Massimo C P Barberis, et al.Current Oncology (Toronto, Ont.)|September 27, 2023
Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort StudyMaria-Josep Carreras, Elena Tomás-Guillén, Anna Farriols, et al.Cancers|July 2, 2021
Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC PatientsAna Callejo, Joan Frigola, Patricia Iranzo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumorsPasi A Jänne, Roger B Cohen, A Douglas Laird, et al.Lung Cancer (Amsterdam, Netherlands)|October 8, 2013
Strategies for improving outcomes in NSCLC: a look to the futureRolf Stahel, Solange Peters, Paul Baas, et al.Journal for Immunotherapy of Cancer|January 12, 2025
Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response predictionKinga Bernatowicz, Ramon Amat, Olivia Prior, et al.Pageof 37